Helse og sykdom hos voksne med downs syndrom

Tidsskrift for den Norske Laegeforening

Volumn 133, Issue 3, 2013, Pages 290-294

  Malt, Eva Albertsen ^a   Dahl, Renate Charlotte ^a   Haugsand, Trine Marie ^a   Ulvestad, Ingebjørg H ^a   Emilsen, Nina Merete ^a   Hansen, Børre ^a   Cardenas, Yon Eduin Galezo ^a   Skøld, Rolf Olof ^a   Thorsen, Anne Tove Berge ^a   Davidsen, Eva Merete Male ^a  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGING; ALZHEIMER DISEASE; CATARACT; CELIAC DISEASE; CONGENITAL HEART MALFORMATION; DOWN SYNDROME; HUMAN; LIFE EXPECTANCY; PERCEPTION DEAFNESS; PREMATURE AGING; REVIEW; SLEEP DISORDERED BREATHING;

ADULT; AGE FACTORS; AGING; AGING, PREMATURE; ALZHEIMER DISEASE; CATARACT; CELIAC DISEASE; DOWN SYNDROME; HEARING LOSS, SENSORINEURAL; HEART DEFECTS, CONGENITAL; HUMANS; LIFE EXPECTANCY; SLEEP APNEA, OBSTRUCTIVE;

MLCS; MLOWN;

EID: 84875309202     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.12.0390     Document Type: Article

References (48)

1. Medisinsk fødselsregister. Medfødte misdannelser, 2010. http://mfr-nesstar.uib.no/mfr/ (15.6.2012).
2. Van Cleve SN, Cohen WI. Part I: Clinical practice guidelines for children with Down syndrome from birth to 12 years. J Pediatr Health Care 2006; 20: 47-54.
3. Van Cleve SN, Cannon S, Cohen WI. Part II: Clinical practice guidelines for adolescents and young adults with Down syndrome: 12 to 21 Years. J Pediatr Health Care 2006; 20: 198-205.
4. Barnhart RC, Connolly B. Aging and Down syndrome: implications for physical therapy. Phys Ther 2007; 87: 1399-406.
5. Zigman WB, Lott IT. Alzheimer's disease in Down syndrome: neurobiology and risk. Ment Retard Dev Disabil Res Rev 2007; 13: 237-46.
6. Hill DA, Gridley G, Cnattingius S et al. Mortality and cancer incidence among individuals with Down syndrome. Arch Intern Med 2003; 163: 705-11.
7. Chaushu S, Yefenof E, Becker A et al. Severe impairment of secretory Ig production in parotid saliva of Down Syndrome individuals. J Dent Res 2002; 81: 308-12.
8. Moore SW. Down syndrome and the enteric nervous system. Pediatr Surg Int 2008; 24: 873-83.
9. Smith DS. Health care management of adults with Down syndrome. Am Fam Physician 2001; 64: 1031-8.
10. Vis JC, Duffels MG, Winter MM et al. Down syndrome: a cardiovascular perspective. J Intellect Disabil Res 2009; 53: 419-25.
11. Dykens EM. Psychiatric and behavioral disorders in persons with Down syndrome. Ment Retard Dev Disabil Res Rev 2007; 13: 272-8.
12. Finesilver C. A new age for childhood diseases. Down syndrome. RN 2002; 65: 43-8, quiz 49.
13. Puri BK, Singh I. Prevalence of cataract in adult Down's syndrome patients aged 28 to 83 years. Clin Pract Epidemol Ment Health 2007; 3: 26.
14. Määttä T, Määttä J, Tervo-Määttä T et al. Healthcare and guidelines: a population-based survey of recorded medical problems and health surveillance for people with Down syndrome. J Intellect Dev Disabil 2011; 36: 118-26.
15. Esbensen AJ. Health conditions associated with aging and end of life of adults with Down syndrome. Int Rev Res Ment Retard 2010; 39 (C): 107-26.
16. Smigielska-Kuzia J, Sobaniec W, Kulak W et al. Clinical and EEG features of epilepsy in children and adolescents in Down syndrome. J Child Neurol 2009; 24: 416-20.
17. Cooper SA, van der Speck R. Epidemiology of mental ill health in adults with intellectual disabilities. Curr Opin Psychiatry 2009; 22: 431-6.
18. Mantry D, Cooper SA, Smiley E et al. The prevalence and incidence of mental ill-health in adults with Down syndrome. J Intellect Disabil Res 2008; 52: 141-55.
19. Haugen OH, Høvding G, Riise R. Øyeforandringer ved Downs syndrom. Tidsskr Nor Lægeforen 2004; 124: 186-8.
20. Goldacre MJ, Wotton CJ, Seagroatt V et al. Cancers and immune related diseases associated with Down's syndrome: a record linkage study. Arch Dis Child 2004; 89: 1014-7.
21. Roizen NJ, Patterson D. Down's syndrome. Lancet 2003; 361: 1281-9.
22. Bergholdt R, Eising S, Nerup J et al. Increased prevalence of Down's syndrome in individuals with type 1 diabetes in Denmark: A nationwide population-based study. Diabetologia 2006; 49: 1179-82.
23. Eaton WW, Pedersen MG, Atladóttir HO et al. The prevalence of 30 ICD-10 autoimmune diseases in Denmark. Immunol Res 2010; 47: 228-31.
24. Goday-Arno A, Cerda-Esteva M, Flores-Le-Roux JA et al. Hyperthyroidism in a population with Down syndrome (DS). Clin Endocrinol (Oxf) 2009; 71: 110-4.
25. Devenny DA, Silverman WP, Hill AL et al. Normal ageing in adults with Down's syndrome: a longitudinal study. J Intellect Disabil Res 1996; 40: 208-21.
26. Rachidi M, Lopes C. Molecular and cellular mechanisms elucidating neurocognitive basis of functional impairments associated with intellectual disability in Down syndrome. Am J Intellect Dev Disabil 2010; 115: 83-112.
27. Lott IT, Dierssen M. Cognitive deficits and associated neurological complications in individuals with Down's syndrome. Lancet Neurol 2010; 9: 623-33.
28. Lanfranchi S, Jerman O, Dal Pont E et al. Executive function in adolescents with Down Syndrome. J Intellect Disabil Res 2010; 54: 308-19.
29. Eastgate G, Scheermeyer E, van Driel ML et al. Intellectual disability, sexuality and sexual abuse prevention-a study of family members and support workers. Aust Fam Physician 2012; 41: 135-9.
30. Martínez-Quintana E, Rodríguez-González F, Medina-Gil JM et al. Clinical outcome in Down syndrome patients with congenital heart disease. Cir Cir 2010; 78: 245-50.
31. Hayek E, Gring CN, Griffin BP. Mitral valve prolapse. Lancet 2005; 365: 507-18.
32. Nagyová A, Sustrová M, Raslová K. Serum lipid resistance to oxidation and uric acid levels in subjects with Down's syndrome. Physiol Res 2000; 49: 227-31.
33. Costa V, Sommese L, Casamassimi A et al. Impairment of circulating endothelial progenitors in Down syndrome. BMC Med Genomics 2010; 3: 40.
34. Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 2002; 359: 1019-25.
35. Solberg KO, Davidsen EM, Lybæk KA et al. Diagnostisering og behandling av personer med utviklingshemming og demens. Ottestad: Habiliteringstjenestene i Helse Øst, 2006. http://ebookbrowse.com/gdoc.php?id=407221037&url=973c78eb5745269d32e3573217d2bdfa (15.6.2012).
36. Lundin KE, Farstad IN, Sollid LM. Cøliaki-nye kliniske erkjennelser og diagnostiske hjelpemidler. Tidsskr Nor Lægeforen 2003; 123: 3226-9.
37. Trois MS, Capone GT, Lutz JA et al. Obstructive sleep apnea in adults with Down syndrome. J Clin Sleep Med 2009; 5: 317-23.
38. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000; 355: 165-9.
39. De Simone R, Puig XS, Gélisse P et al. Senile myoclonic epilepsy: delineation of a common condition associated with Alzheimer's disease in Down syndrome. Seizure 2010; 19: 383-9.
40. Down JLH. Observations on an ethnic classification of idiots. London Hospital Reports 1866; 3: 259-62.
41. Hippolyte L, Iglesias K, Van der Linden M et al. Social reasoning skills in adults with Down syndrome: the role of language, executive functions and socio-emotional behaviour. J Intellect Disabil Res 2010; 54: 714-26.
42. Vanvuchelen M, Feys H, De Weerdt W. Is the goodimitator-poor-talker profile syndrome-specific in Down syndrome?: evidence from standardised imitation and language measures. Res Dev Disabil 2011; 32: 148-57.
43. Capone G, Goyal P, Ares W et al. Neurobehavioral disorders in children, adolescents, and young adults with Down syndrome. Am J Med Genet C Semin Med Genet 2006; 142C: 158-72.
44. Zigman WB, Schupf N, Urv T et al. Incidence and temporal patterns of adaptive behavior change in adults with mental retardation. Am J Ment Retard 2002; 107: 161-74.
45. Schupf N, Pang D, Patel BN et al. Onset of dementia is associated with age at menopause in women with Down's syndrome. Ann Neurol 2003; 54: 433-8.
46. Lee JH, Gurney S, Pang D et al. Polymorphisms in HSD17B1: Early onset and increased risk of Alzheimer's disease in women with Down syndrome. Curr Gerontol Geriatr Res 2012; 2012: 361218.
47. Kondoh T, Kanno A, Itoh H et al. Donepezil significantly improves abilities in daily lives of female Down syndrome patients with severe cognitive impairment: a 24-week randomized, double-blind, placebo-controlled trial. Int J Psychiatry Med 2011; 41: 71-89.
48. Hanney M, Prasher V, Williams N, et al. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 379: 528-36.